Given that IgAN is a common cause of glomerular disease and CKD, large numbers of patients with IgAN were included in the DAPA-CKD and EMPA-KIDNEY trials of SGLT2 inhibitors in non-diabetic CKD. The gene discussed is SLC5A2; the disease is chronic kidney disease.